|
Myeloid Neoplasia
Citations 1-10 of 168 total displayed.
|
Most recent content
(12 Nov 2009):
|
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
- Ravin J. Garg, Hagop Kantarjian, Susan O'Brien, Alfonso Quintás-Cardama, Stefan Faderl, Zeev Estrov, and Jorge Cortes
Blood 2009; 114: 4361-4368.
[Abstract]
[Full text]
[PDF]
The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways
- Mohamed Rahmani, Anh Anderson, Joseph Reza Habibi, Timothy Ryan Crabtree, Mandy Mayo, Hisashi Harada, Andrea Ferreira-Gonzalez, Paul Dent, and Steven Grant
Blood 2009; 114: 4507-4516.
[Abstract]
[Full text]
[PDF]
|
Past content
(since Jan 2009):
|
Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal
- Michael Heuser, Laura M. Sly, Bob Argiropoulos, Florian Kuchenbauer, Courteney Lai, Andrew Weng, Malina Leung, Grace Lin, Christy Brookes, Stephen Fung, Peter J. Valk, Ruud Delwel, Bob Löwenberg, Gerald Krystal, and R. Keith Humphries
Blood 2009; 114: 3983-3993.
[Abstract]
[Full text]
[PDF]
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse
- Francis Giles, Norbert Vey, Daniel DeAngelo, Karen Seiter, Wendy Stock, Robert Stuart, Darinka Boskovic, Arnaud Pigneux, Martin Tallman, Joseph Brandwein, Jonathan Kell, Tadeusz Robak, Peter Staib, Xavier Thomas, Ann Cahill, Maher Albitar, and Susan O'Brien
Blood 2009; 114: 4027-4033.
[Abstract]
[Full text]
[PDF]
BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38– cells, through activation of protein kinase Cβ
- Francesca Pellicano, Mhairi Copland, Heather G. Jorgensen, Joanne Mountford, Brian Leber, and Tessa L. Holyoake
Blood 2009; 114: 4186-4196.
[Abstract]
[Full text]
[PDF]
E3 ligase–defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease
- Srinivasa Rao Bandi, Christian Brandts, Marion Rensinghoff, Rebekka Grundler, Lara Tickenbrock, Gabriele Köhler, Justus Duyster, Wolfgang E. Berdel, Carsten Müller-Tidow, Hubert Serve, on behalf of the Study Alliance Leukemias, and Bülent Sargin
Blood 2009; 114: 4197-4208.
[Abstract]
[Full text]
[PDF]
How I treat hypereosinophilic syndromes
- Amy D. Klion
Blood 2009; 114: 3736-3741.
[Abstract]
[Full text]
[PDF]
Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies
- Animesh Pardanani, Ken-Hong Lim, Terra L. Lasho, Christy Finke, Rebecca F. McClure, Chin-Yang Li, and Ayalew Tefferi
Blood 2009; 114: 3769-3772.
[Abstract]
[Full text]
[PDF]
Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia
- Qing Zhou, Christoph Bucher, Meghan E. Munger, Steven L. Highfill, Jakub Tolar, David H. Munn, Bruce L. Levine, Megan Riddle, Carl H. June, Daniel A. Vallera, Brenda J. Weigel, and Bruce R. Blazar
Blood 2009; 114: 3793-3802.
[Abstract]
[Full text]
[PDF]
Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome
- Britta Will, Masahiro Kawahara, Julia P. Luciano, Ingmar Bruns, Samir Parekh, Connie L. Erickson-Miller, Manuel A. Aivado, Amit Verma, and Ulrich Steidl
Blood 2009; 114: 3899-3908.
[Abstract]
[Full text]
[PDF]
|
|
